Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
PLoS One. 2012;7(4):e34321. doi: 10.1371/journal.pone.0034321. Epub 2012 Apr 9.
The efficient commitment of a specialized cell type from induced pluripotent stem cells (iPSCs) without contamination from unknown substances is crucial to their use in clinical applications. Here, we propose that CD34+ progenitor cells, which retain hematopoietic and endothelial cell potential, could be efficiently obtained from iPSCs derived from human bone marrow mesenchymal stem cells (hBMMSC-iPSCs) with defined factors. By treatment with a cocktail containing mesodermal, hematopoietic, and endothelial inducers (BMP4, SCF, and VEGF, respectively) for 5 days, hBMMSC-iPSCs expressed the mesodermal transcription factors Brachyury and GATA-2 at higher levels than untreated groups (P<0.05). After culturing with another hematopoietic and endothelial inducer cocktail, including SCF, Flt3L, VEGF and IL-3, for an additional 7-9 days, CD34+ progenitor cells, which were undetectable in the initial iPSC cultures, reached nearly 20% of the total culture. This was greater than the relative number of progenitor cells produced from human-skin-fibroblast-derived iPSCs (hFib-iPSCs) or from the spontaneous differentiation groups (P<0.05), as assessed by flow cytometry analysis. These induced cells expressed hematopoietic transcription factors TAL-1 and GATA-2 [corrected]. They developed into various hematopoietic colonies when exposed to semisolid media with hematopoietic cytokines such as EPO and G-CSF. Hematopoietic cell lineages were identified by phenotype analysis with Wright-Giemsa staining. The endothelial potential of the cells was also verified by the confirmation of the formation of vascular tube-like structures and the expression of endothelial-specific markers CD31 and VE-CADHERIN. Efficient induction of CD34+ progenitor cells, which retain hematopoietic and endothelial cell potential with defined factors, provides an opportunity to obtain patient-specific cells for iPSC therapy and a useful model for the study of the mechanisms of hematopoiesis and drug screening.
从诱导多能干细胞 (iPSC) 中高效地获得特定细胞类型,而不被未知物质污染,对于其在临床应用中的使用至关重要。在这里,我们提出可以通过使用定义因子从源自人骨髓间充质干细胞 (hBMMSC-iPSC) 的 iPSC 中高效获得保留造血和内皮细胞潜能的 CD34+祖细胞。通过用包含中胚层、造血和内皮诱导剂(分别为 BMP4、SCF 和 VEGF)的鸡尾酒处理 5 天,hBMMSC-iPSC 表达的中胚层转录因子 Brachyury 和 GATA-2 的水平高于未处理组(P<0.05)。在用另一种包含 SCF、Flt3L、VEGF 和 IL-3 的造血和内皮诱导剂鸡尾酒培养另外 7-9 天后,初始 iPSC 培养物中无法检测到的 CD34+祖细胞达到了总培养物的近 20%。这比从人皮肤成纤维细胞衍生的 iPSC(hFib-iPSC)或自发分化组产生的祖细胞的相对数量更大(P<0.05),通过流式细胞术分析评估。这些诱导细胞表达造血转录因子 TAL-1 和 GATA-2 [已更正]。当暴露于含有造血细胞因子(如 EPO 和 G-CSF)的半固体培养基中时,它们发育成各种造血集落。通过用 Wright-Giemsa 染色进行表型分析鉴定造血细胞谱系。通过确认血管管状结构的形成和内皮特异性标志物 CD31 和 VE-CADHERIN 的表达,还验证了细胞的内皮潜能。通过使用定义因子高效诱导保留造血和内皮细胞潜能的 CD34+祖细胞,为获得用于 iPSC 治疗的患者特异性细胞提供了机会,并且为研究造血机制和药物筛选提供了有用的模型。